Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Spanish plasma-derived medicines company Grifols announced with the Andorran government the cancellation of the immunology research center planned for the parish of Ordino. 29 July 2024
The US Food and Drug Administration (FDA) approved Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages one through three years. 27 July 2024
Vividion Therapeutics, a wholly-owned subsidiary of Germany’s Bayer, today announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. 23 July 2024
US pharm major Eli Lilly on Friday revealed via a social media posting that it has been granted approval from the Chinese National Medical Products Administration (NMPA) to sell tirzepatide for weight loss in the country. 20 July 2024
The US Food and Drug Administration (FDA) issued a draft guidance for industry, “Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment,” to help sponsors in the clinical development of drugs to treat pediatric patients with inflammatory bowel disease (IBD). 19 July 2024
Zevra Therapeutics revealed that the US Food and Drug Administration (FDA) has indicated it will convene a meeting with the recently formed Genetic Metabolic Diseases Advisory Committee (GeMDAC) on August 2, 2024, to review the New Drug Application (NDA) for arimoclomol. 15 July 2024
The pharma sector continues to maintain strong levels of public trust and favorability among Britons, according to the Association of the British Pharmaceutical Industry (ABPI) UK Pharma Reputation Index. 29 August 2023
Ireland-incorporated specialty pharma firm Mallinckrodt Pharmaceuticals said last week that it planned to file for bankruptcy for the second time in three years. 27 August 2023
Germany’s Bayer has announced that Dr Juergen Eckhardt is to be the new head of business development and licensing / open innovation (BDL/OI) of its Pharmaceuticals Division effective September 1, 2023. 25 August 2023
Danish allergy immunotherapy specialist ALK Abello has posted financial results showing that revenue grew by 11% to 1.14 billion kroner ($165 million) in the second quarter of 2023. 25 August 2023
The trade body for the British pharmaceutical industry has issued a response to a report from the Journal of Royal Society of Medicine, which raised concerns about the Innovative Medicines Fund. 25 August 2023
The US Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the use of Veklury (remdesivir) with no dose adjustments to treat COVID-19 in people with mild, moderate and severe hepatic impairment. 24 August 2023
Fulcrum Therapeutics saw its shares gain as much as 48.5% to $5.82 pre-market yesterday following an update from the US Food and Drug Administration (FDA). 23 August 2023
Exelixis and Ipsen have announced that the Phase III CONTACT-02 pivotal trial met one of two primary endpoints, demonstrating a statistically-significant improvement in progression-free survival (PFS) at the primary analysis. 22 August 2023
Sweden-based IRLAB Therapeutics has secured full global rights ownership of mesdopetam, the company’s leading asset, which was previously out-licensed to French drugmaker Ipsen. 22 August 2023
Medicines for Malaria Venture (MMV) today revealed that Brazil has become the first malaria-endemic country to approve the use of single-dose tafenoquine (Kozenis) for children aged two years and above in combination with chloroquine. 22 August 2023
Leading Russian drugmakers are expanding in the Latin American region by beginning to supply their drugs to regional markets and strengthening of their local presence. 22 August 2023
The second quarter (Q2) of 2023 brought positive outcomes in market capitalization for the leading 20 biopharma companies, despite wider inflationary pressures. 21 August 2023
US rare and orphan dermatologic diseases firm Timber Pharmaceuticals saw it shares almost double to $2.79 this morning, on the news of a takeover bid. 21 August 2023
Global drugmakers operating in Russia have almost completely suspended clinical trials of their new original drugs in the local market, reports The Pharma Letter’s local correspondent. 21 August 2023
UK addiction treatment specialist Indivior (LSE/Nasdaq: INDV) saw its shares edge up 3% to 1,812 pence by early afternoon, as it revealed a resolution to the claims brought by the end payor class of litigants in the In re Suboxone Antitrust Litigation multi-district litigation (MDL). 21 August 2023
The US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for French privately-held drugmaker Servier’s Tibsovo (ivosidenib tablets) in the treatment of patients with isocitrate dehydrogenase 1 (IDH1)-mutated relapsed or refractory (R/R) myelodysplastic syndromes (MDS). 21 August 2023
Companies supplying medicines in Australia will be required to provide additional information to the Therapeutic Goods Administration (TGA) if their products go into shortage. 21 August 2023
Although Latin America has a broad portfolio of innovative medicines to treat orphan diseases and cancer, only 13% of patients who would benefit from these therapies have access to them. 18 August 2023